All Stories

  1. Diversity of domestic and imported assemblages of Giardia in Norway and multi-locus sequence typing of domestic assemblage A isolates
  2. Cryptosporidium infection and associated factors among diarrheic children under five years of age in Eastern Ethiopia
  3. Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection
  4. Development of Protective Immunity Against Diarrheal Disease in Early Years of Life
  5. Inflammation, the kynurenines, and mucosal injury during human experimental enterotoxigenic Escherichia coli infection
  6. Colicins and T6SS-based competition systems enhance enterotoxigenic E. coli (ETEC) competitiveness
  7. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops
  8. Reduced Plasma Guanylin Levels Following Enterotoxigenic Escherichia coli-Induced Diarrhea
  9. Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic Escherichia coli infection
  10. Genetic diversity in the metronidazole metabolism genes nitroreductases and pyruvate ferredoxin oxidoreductases in susceptible and refractory clinical samples of Giardia lamblia
  11. Highly contiguous genomes of human clinical isolates of Giardia duodenalis reveal assemblage- and sub-assemblage-specific presence–absence variation in protein-coding genes
  12. Strong Association between Diarrhea and Concentration of Enterotoxigenic Escherichia coli Strain TW10722 in Stools of Experimentally Infected Volunteers
  13. Oocyst Shedding Dynamics in Children with Cryptosporidiosis: a Prospective Clinical Case Series in Ethiopia
  14. A comparison of risk factors for cryptosporidiosis and non-cryptosporidiosis diarrhoea: A case-case-control study in Ethiopian children
  15. Conserved metabolic enzymes as vaccine antigens for giardiasis
  16. Transition to PCR diagnosis of cryptosporidiosis and giardiasis in the Norwegian healthcare system: could the increase in reported cases be due to higher sensitivity or a change in the testing algorithm?
  17. No difference in serum levels of B‐cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post‐infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection
  18. Characterization of Glycosylation-Specific Systemic and Mucosal IgA Antibody Responses to Escherichia coli Mucinase YghJ (SslE)
  19. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders
  20. A site assessment tool for inpatient controlled human infection models for enteric disease pathogens
  21. Prevalence of fibromyalgia 10 years after infection with Giardia lamblia: a controlled prospective cohort study
  22. Clinical features of gastroenteritis during a large waterborne Campylobacter outbreak in Askøy, Norway
  23. Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study
  24. Characteristics of hospitalized patients during a large waterborne outbreak of Campylobacter jejuni in Norway
  25. <p>Genetic Diversity of the Flavohemoprotein Gene of Giardia lamblia: Evidence for High Allelic Heterozygosity and Copy Number Variation</p>
  26. The Intriguing Interaction of Escherichia coli with the Host Environment and Innovative Strategies To Interfere with Colonization: a Summary of the 2019 E. coli and the Mucosal Immune System Meeting
  27. Bacteraemia, Malaria, and Case Fatality Among Children Hospitalized With Fever in Dar es Salaam, Tanzania
  28. Human Mucosal IgA Immune Responses against Enterotoxigenic Escherichia coli
  29. Giardiasis treatment: an update with a focus on refractory disease
  30. Comparative expression profiling in the intestine of patients with Giardia ‐induced postinfectious functional gastrointestinal disorders
  31. Plasma levels of guanylins are reduced in patients with Crohn’s disease
  32. Monocytes from neonates and adults have a similar capacity to adapt their cytokine production after previous exposure to BCG and β-glucan
  33. Whole blood preservation methods alter chemokine receptor detection in mass cytometry experiments
  34. A new human challenge model for testing heat-stable toxin-based vaccine candidates for enterotoxigenic Escherichia coli diarrhea – dose optimization, clinical outcomes, and CD4+ T cell responses
  35. Prolonged and persistent diarrhoea is not restricted to children with acute malnutrition: an observational study in Ethiopia
  36. The way forward for ETEC controlled human infection models (CHIMs)
  37. Assessment of malaria real-time PCR methods and application with focus on low-level parasitaemia
  38. Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing Enterotoxigenic Escherichia coli Strain TW11681
  39. Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia
  40. Genetic variation in metronidazole metabolism and oxidative stress pathways in clinical Giardia lamblia assemblage A and B isolates
  41. Quality of life and its association with irritable bowel syndrome and fatigue ten years after giardiasis
  42. Prolonged Duodenal Mucosal Lymphocyte Alterations in Patients With and Without Postinfectious Functional Gastrointestinal Disorders After Giardia Infection
  43. Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea
  44. Proliferation of enterotoxigenic Escherichia coli strain TW11681 in stools of experimentally infected human volunteers
  45. Treatment-refractory giardiasis: challenges and solutions
  46. Longitudinal cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area
  47. Prevalence of Irritable Bowel Syndrome and Chronic Fatigue 10 Years After Giardia Infection
  48. Transient elevation of anti-transglutaminase and anti-endomysium antibodies in Giardia infection
  49. Giardiasis: a diagnosis that should be considered regardless of the setting
  50. Genetic variation in potential Giardia vaccine candidates cyst wall protein 2 and α1-giardin
  51. Comprehensive Analysis of Prevalence, Epidemiologic Characteristics, and Clinical Characteristics of Monoinfection and Coinfection in Diarrheal Diseases in Children in Tanzania
  52. Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome
  53. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency
  54. Long-Term Consequences of Cryptosporidium and Giardia Gastroenteritis
  55. Editorial Commentary:Giardia lamblia–Pathogen or Commensal?
  56. Excessive daytime sleepiness, sleep need and insomnia 3 years after Giardia infection: a cohort study
  57. Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis
  58. Perceived food intolerance and irritable bowel syndrome in a population 3 years after a giardiasis-outbreak: a historical cohort study
  59. Prevalence of Cryptosporidium parvum/hominis, Entamoeba histolytica and Giardia lamblia among Young Children with and without Diarrhea in Dar es Salaam, Tanzania
  60. Human Memory CD4+T Cell Immune Responses against Giardia lamblia
  61. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection
  62. Whole genome sequencing of clinical isolates of Giardia lamblia
  63. Intestinal Microbiota And Diet in IBS: Causes, Consequences, or Epiphenomena?
  64. Hund som Giardia-kilde i Bergen i 2004 – barking up the wrong tree?
  65. Prevalence and molecular characterisation of human adenovirus in diarrhoeic children in Tanzania; a case control study
  66. Secondary transmission of Cryptosporidium parvum
  67. Irritable Bowel Syndrome and Chronic Fatigue 6 Years After Giardia Infection: A Controlled Prospective Cohort Study
  68. Genetic diversity of norovirus in hospitalised diarrhoeic children and asymptomatic controls in Dar es Salaam, Tanzania
  69. Management of chronicGiardiainfection
  70. Comparison of four methods for extracting DNA from dried blood on filter paper for PCR targeting the mitochondrial Plasmodium genome
  71. Genetic Diversity of Circulating Rotavirus Strains in Tanzania Prior to the Introduction of Vaccination
  72. En ung kvinne med langvarig diaré og slapphet
  73. Giardia-infeksjon kan gi irritabel tarm og kronisk utmattelse
  74. Praktisk anlagt oppslagsbok om tropemedisin
  75. Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course
  76. A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway
  77. The role of arginine and arginine-metabolizing enzymes during Giardia – host cell interactions in vitro
  78. Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome
  79. The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years afterGiardiainfection. A historic cohort study
  80. Human Cellular Immune Response Against Giardia lamblia 5 Years After Acute Giardiasis
  81. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study
  82. Tolerability and effect of mesalazine in postinfectious irritable bowel syndrome
  83. Giardiasis: The Ever-Present Threat of a Neglected Disease
  84. Post epidemic giardiasis and gastrointestinal symptoms among preschool children in Bergen, Norway. A cross-sectional study
  85. Giardiasis – why do the symptoms sometimes never stop?
  86. Relative importance of abnormalities of CCK (cholecystokinin) and 5-HT (serotonin) inGiardia-induced post-infectious irritable bowel syndrome and functional dyspepsia
  87. Severity of Giardiainfection associated with post-infectious fatigue and abdominal symptoms two years after
  88. High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis
  89. Development of functional gastrointestinal disorders after Giardia lambliainfection
  90. Sensitivity of a Giardia antigen test in persistent giardiasis following an extensive outbreak
  91. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway
  92. Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: A randomized open clinical trial
  93. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection
  94. Landmine injuries in Eritrea